INLB Stock Overview
Operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Item 9 Labs Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.004 |
52 Week Low | US$0.000001 |
Beta | 0.49 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -99.96% |
33 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
INLB | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 1.6% | 2.2% |
1Y | -100.0% | 10.0% | 31.7% |
Return vs Industry: INLB underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: INLB underperformed the US Market which returned 31.1% over the past year.
Price Volatility
INLB volatility | |
---|---|
INLB Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INLB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine INLB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | www.item9labscorp.com |
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona.
Item 9 Labs Corp. Fundamentals Summary
INLB fundamental statistics | |
---|---|
Market cap | US$701.00 |
Earnings (TTM) | -US$31.03m |
Revenue (TTM) | US$19.69m |
0.0x
P/S Ratio0.0x
P/E RatioIs INLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INLB income statement (TTM) | |
---|---|
Revenue | US$19.69m |
Cost of Revenue | US$9.89m |
Gross Profit | US$9.80m |
Other Expenses | US$40.84m |
Earnings | -US$31.03m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.044 |
Gross Margin | 49.79% |
Net Profit Margin | -157.61% |
Debt/Equity Ratio | 64.4% |
How did INLB perform over the long term?
See historical performance and comparison